Industrial policy is where Nigerian intentions go to die — that was the reasonable prior for three decades of "we will manufacture our own medicines" announcements. Which is why NAFDAC's 5+5 policy deserves the discipline of actual numbers rather than vibes. The numbers, for once, are good. But they also reveal the policy's unresolved flank.
What the Policy Actually Does
Introduced in 2018 under Director-General Prof. Mojisola Christianah Adeyeye, the 5+5 mechanism is elegant in its simplicity: for medicines that can be produced locally, new registrations are restricted to foreign manufacturers who partner with a Nigerian company, with registrations granted for five years and renewable for five more conditional on progressive localisation of production.
The policy weaponised the one asset every foreign manufacturer wants — access to Africa's largest consumer market by population — and priced it in local capacity. It is import-substitution, but surgical: not a tariff wall, a partnership gate.
The Results, as of 2026
NAFDAC's own published accounting provides the scoreboard:
- 191 applications processed; 97% (185) approved as of March 2026 — the overwhelming majority structured as foreign–local manufacturing partnerships.
- Local production has risen to roughly half of Nigeria's pharmaceutical needs, from a position where imports historically dominated.
- At least 11 pharmaceutical manufacturing projects were slated for commissioning in 2026.
- International validation: Nigeria's essential-medicines scale-up featured as a case study in the UNIDO Industrial Development Report 2026, and the sector is pushing toward WHO Maturity Level 3 regulatory status — the threshold at which agencies are considered robust national authorities.
- The direction is codified: national policy targets 70% local production by 2030.
For context on what that base represents: the market stands around $1.7 billion with ~9% annual growth, and import dependence had already fallen from roughly 70% toward 60% of needs. Facilities like Emzor's $23 million API plant in Sagamu — the first of its kind in the sub-region — signal the next chapter: moving upstream from formulation to ingredients.
The Winners
Local manufacturers — first and most obviously. Mandated partnership converted foreign firms from competitors into clients and co-investors. Capacity that would have taken decades to finance from retained earnings is being built now.
The regulatory agency itself. The policy worked because NAFDAC made itself credible first — the push toward WHO ML3 and the reliance guidelines (adopting assessments from trusted regulators) raised the agency's standing and, with it, the enforceability of its instruments.
The workforce. Every commissioned plant absorbs pharmacists, chemists, and engineers — the demand side of the story we map in the industrial career guide.
Health security. The pandemic taught the world what supply-chain dependency costs. A country producing half its medicines is structurally safer than one producing a quarter.
The Losers — Stated Plainly
Pure importers. Firms whose model was registering and importing locally producible medicines lost protected ground — that was the policy's explicit intent. Some have adapted by taking equity in local plants; the policy rewarded exactly that adaptation.
Consumers, in the short term, on price. Local production is not automatically cheaper production — power, logistics, and import duty on inputs can make domestic cost structures uncompetitive. The consumer dividend arrives with scale, competition among local producers, and input localisation (APIs). Anyone who tells you the policy made drugs cheaper yesterday is selling something.
The Treasury, briefly. Forgone import-registration activity has a fiscal shadow. The policy is a long-duration bet that industrial capacity returns more than fees — the evidence so far supports it, but honesty requires stating the trade.
The Unresolved Flank: Upstream Dependence
Formulating tablets in Sagamu with imported APIs is industrialisation at half-depth. The Emzor API plant and projects like it address the deepest dependency — but API localisation is capital-intensive and unforgiving, and the sector's next decade will be judged on it as much as on formulation capacity. Power reliability and logistics costs remain the permanent tax on Nigerian manufacturing that policy has not yet repealed.
What Comes Next
- From formulation to ingredients. Watch API and excipient localisation — that is where "60%" becomes a real industrial base.
- Quality consolidation. WHO ML3 status, sustained GMP enforcement, and rationalisation of sub-scale producers.
- Regional export. A compliant Nigerian industry under AfCFTA is not just import substitution — it is a West African export platform.
- Policy durability. The single greatest risk to all of the above is reversal by a future administration. The Academy's stated position — articulated at its recent investitures — is that pharmaceutical innovation and local capacity are national-development priorities that must outlive political cycles.
The 5+5 policy is the rarest thing in Nigerian industrial policy: an intervention with a scoreboard worth reading. The next chapter — ingredients, quality, exports — will decide whether it was a success or merely a start.
For the workforce implications, see where the manufacturing jobs will be; for the original operational guidance, our 5+5 directive explainer remains the reference. Subscribe to NAPharm Insights for the policy tracking that industry decision-makers rely on.
